All In Biotech

Drug Trial Radar · NCT04937829

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Randomized, Double-blind (Patient, Investigator), Placebo-controlled, Parallel Group, Single Dosing Study on Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of BI 1569912 as Adjunctive Therapy in Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

59

Actual

Start

Jul 20, 2021

Primary completion

Nov 16, 2023

Study completion Nov 16, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study. This study is for people for whom existing treatments for depression do not work sufficiently. The purpose of this study is to test how well a medicine called BI 1569912 is tolerated and whether it may help people with depression. It is planned to test 4 different dosages of BI 1569912 in this study. Each participant gets either one BI 1569912 dosage or placebo. It is decided randomly, which means by chance, who gets which treatment. Participants take BI 1569912 or placebo as tablets once during the study. Placebo tablets look like BI 1569912 tablets but do not contain any medicine. Participants also continue taking their usual medicine for depression throughout the study. Participants are in the study for about 5 weeks. During this time, they visit the study site 4 times, with a stay at the study site for 9 days. The doctors check the health of the participants and note any health problems that could have been caused by BI 1569912. The participants fill in questionnaires about their depression symptoms.

Conditions

  • Depressive Disorder, Major

Interventions

  • 5 mg BI 1569912Drug

    BI 1569912Moderate-to-severe Major Depressive Disorder (MDD) patients on stable antidepressants (i.e. selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)) took a single dose of 5 milligram (mg) BI 1569912 (1 BI 1569912 5 mg tablet and 3 placebo tablets), orally in the morning.

  • 20 mg BI 1569912Drug

    Moderate-to-severe Major Depressive Disorder (MDD) patients on stable antidepressants (i.e. selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)) took a single dose of 20 milligram (mg) BI 1569912 (4 BI 1569912 5 mg tablets), taken orally in the morning.

  • PlaceboDrug

    Moderate-to-severe Major Depressive Disorder (MDD) patients on stable antidepressants (i.e. selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)) took four placebo tablets matching in size and weight to BI 1569912 5 mg tablets, taken orally in the morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Decrease From Baseline (Peak Decrease) in Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Any Day Within a 7-day IntervalTime frame: Evaluations taken at baseline (day -63 to -3) and on day 1, 2, 4, 6 and 8 (with trial drug intake on day 1).
  2. Number of Patients With Drug-related Adverse EventsTime frame: The on treatment period + Follow up period, up to 15 days.

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network, LLC (CNS)

    Garden Grove, California

  • Collaborative Neuroscience Research, LLC

    Torrance, California

  • Optimus U Corporation

    Miami, Florida

  • Research Centers of America

    Oakland Park, Florida

  • iResearch Atlanta

    Decatur, Georgia

  • Hassman Research Institute

    Berlin, New Jersey

  • Hassman Research Institute

    Marlton, New Jersey

  • Neuro-Behavioral Clinical Research

    North Canton, Ohio

  • InSite Clinical Research

    DeSoto, Texas

  • Pillar Clinical Research, LLC

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.